Getinge AB (STU:GTN) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GTN Getinge AB STU:GTN
77 GF Score
Price €21.90
GF Value €18.53
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Getinge AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:GTN
77GF Score
Getinge AB STU:GTN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Getinge AB (STU:GTN) Overvalued in 2026?

Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued. The current stock price of €21.90 is trading 18.2% above its estimated GF Value™ of €18.53. GuruFocus considers Getinge AB to be Modestly Overvalued.

Key valuation signals for STU:GTN:

  • Dividends Received:
  • GF Value™: €18.53 vs. price of €21.90 (18.2% above fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the STU:GTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Getinge AB Business Description

Address Lindholmspiren 7A, P.O. Box 8861, Gothenburg, SWE, 417 56
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
77GF Score

Get the complete analysis for STU:GTN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.90
Price
€18.53
GF Value